ETH-CAT: Difference between revisions

>Discount Pharmacologist
m Removed broken link
>Blackhole
added legal status for switzerland
 
(7 intermediate revisions by 5 users not shown)
Line 2: Line 2:
{{SubstanceBox/ETH-CAT}}
{{SubstanceBox/ETH-CAT}}


'''Ethylcathinone''' (also known as '''Ethylpropion''', '''Ethcathinone''', and commonly as '''ETH-CAT''') is a [[psychoactive class::stimulant]] substance of the [[chemical class::cathinone]] chemical class that produces [[stimulating]] and [[focus enhancement|focus enhancing]] effects when [[Routes of administration|administered]]. It is structurally related to [[cathinone]] and methcathinone (MCAT), which broadly shares the effects profile of [[amphetamine]] or [[methylphenidate]].  
'''Ethylcathinone''' (also known as '''Ethylpropion''', '''Ethcathinone''', and commonly as '''ETH-CAT''') is a [[psychoactive class::stimulant]] substance of the [[chemical class::cathinone]] chemical class that produces [[stimulating]] and [[focus enhancement|focus enhancing]] effects when [[Routes of administration|administered]]. It is structurally related to [[cathinone]] and [[methcathinone]] (MCAT), which broadly shares the effects profile of [[amphetamine]] or [[methylphenidate]].  


Of the [[substituted cathinones]], ETH-CAT reportedly produces the most moderate and residually long-lasting stimulation, with subtle effects that persist well after the initial rush. It has been described as having a more functional than recreational character due to the limited euphoria it produces for a stimulant, although its short active duration can promote [[compulsive redosing]].
Of the [[substituted cathinones]], ETH-CAT reportedly produces the most moderate and residually long-lasting stimulation, with subtle effects that persist well after the initial rush. It has been described as having a more functional than recreational character due to the limited euphoria it produces for a stimulant, although its short active duration can promote [[compulsive redosing]].


Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-CAT, and it has little history of human usage. It is primarily distributed as a [[research chemical]] on the online grey market.<ref>Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/15639609</ref><ref>Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/20074881</ref> In 2008 it was identified as an ingredient in both quasi-legal "party pills". It has also been reported as having been sold as "ecstasy" along with another [[substituted cathinone]], [[mephedrone]].<ref>Police warn of potentially fatal 'fake ecstasy' | http://www.abc.net.au/news/2008-06-17/police-warn-of-potentially-fatal-fake-ecstasy/2475270</ref> It is highly advised to use harm reduction practices if using this substance.  
Very little data exists about the pharmacological properties, metabolism, and toxicity of ETH-CAT, and it has little history of human usage. It is primarily distributed as a [[research chemical]] on the online grey market.<ref>{{cite journal | vauthors=((Rösner, P.)), ((Quednow, B.)), ((Girreser, U.)), ((Junge, T.)) | journal=Forensic Science International | title=Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs) | volume=148 | issue=2–3 | pages=143–156 | date=10 March 2005 | issn=0379-0738 | doi=10.1016/j.forsciint.2004.05.003}}</ref><ref>{{cite journal | vauthors=((Camilleri, A.)), ((Johnston, M. R.)), ((Brennan, M.)), ((Davis, S.)), ((Caldicott, D. G. E.)) | journal=Forensic Science International | title=Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone | volume=197 | issue=1–3 | pages=59–66 | date=15 April 2010 | issn=1872-6283 | doi=10.1016/j.forsciint.2009.12.048}}</ref> In 2008 it was identified as an ingredient in both quasi-legal "party pills". It has also been reported as having been sold as "ecstasy" along with another [[substituted cathinone]], [[mephedrone]].<ref>{{Citation | year=2008 | title=Police warn of potentially fatal “fake ecstasy” | url=https://www.abc.net.au/news/2008-06-17/police-warn-of-potentially-fatal-fake-ecstasy/2475270}}</ref> It is highly advised to use harm reduction practices if using this substance.  


==Chemistry==
==Chemistry==
Line 16: Line 16:


==Pharmacology==
==Pharmacology==
Although the effects of ETH-CAT have not been formally studied on the same level as traditional [[amphetamines]] or other substituted cathinones like [[methcathinone]], it is possible to speculate that like other simple [[substituted cathinone]], it most likely acts principally as a [[dopamine]] and [[norepinephrine]] [[reuptake inhibitor]].<ref>Kelly, J. P. (2011). Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. ''Drug Testing and Analysis'', 3(7‐8), 439-453. https://doi.org/10.1002/dta.31</ref>  
Although the effects of ETH-CAT have not been formally studied on the same level as traditional [[amphetamines]] or other substituted cathinones like [[methcathinone]], it is possible to speculate that like other simple [[substituted cathinone]], it most likely acts principally as a [[dopamine]] and [[norepinephrine]] [[reuptake inhibitor]].<ref>{{cite journal | vauthors=((Deventer, K.)), ((Van Eenoo, P.)), ((Baele, G.)), ((Pozo, O. J.)), ((Van Thuyne, W.)), ((Delbeke, F. T.)) | journal=Drug Testing and Analysis | title=Interpretation of urinary concentrations of pseudoephedrine and its metabolite cathine in relation to doping control | volume=1 | issue=5 | pages=209–213 | date= May 2009 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.31 | issn=19427603 | doi=10.1002/dta.31}}</ref> It however has been shown that ETH-CAT is a selective substrate for the norepinephrine transporter (NET).<ref>{{cite book | vauthors=((Trachsel, D.)), ((Lehmann, D.)), ((Enzensperger, C.)) | date= 2013 | title=Phenethylamine: von der Struktur zur Funktion | publisher=Nachtschatten Verlag | series=Edition Nachtschatten Science | isbn=9783037887004}}</ref>


The result of this is an effective increase in the levels of [[catecholamine]] [[neurotransmitters]] like [[dopamine]] and [[norepinephrine]] in the brain by binding to and partially blocking the transporter proteins that normally clear these neurotransmitters from the synaptic cleft. This enables dopamine and norepinephrine to accumulate between the [[synaptic cleft|synaptic clefts]] of key regions of the brain associated with reward, motivation, satisfaction and pleasure to extra-endogenous levels. This mechanism is thought to account for the [[Stimulation|stimulating]], [[Motivation enhancement|motivation enhancing]] and [[Euphoria|euphoric]] effects that this substance produces.
The result of this is an effective increase in the levels of [[catecholamine]] [[neurotransmitters]] like [[dopamine]] and [[norepinephrine]] in the brain by binding to and partially blocking the transporter proteins that normally clear these neurotransmitters from the synaptic cleft. This enables dopamine and norepinephrine to accumulate between the [[synaptic cleft|synaptic clefts]] of key regions of the brain associated with reward, motivation, satisfaction and pleasure to extra-endogenous levels. This mechanism is thought to account for the [[Stimulation|stimulating]], [[Motivation enhancement|motivation enhancing]] and [[Euphoria|euphoric]] effects that this substance produces.
Line 87: Line 87:
===Psychosis===
===Psychosis===
{{Main|Stimulant psychosis}}
{{Main|Stimulant psychosis}}
Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[paranoia]], [[External hallucinations|hallucinations]], or [[delusions]]).<ref name="amptreat">Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database of Systematic Reviews'', 1. https://doi.org/10.1002/14651858.CD003026.pub3 ''</ref> A review on treatment for [[amphetamine]] and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref name="amptreat" /><ref>Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects. Oxford University Press. ISBN 9780195030570.</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref name="amptreat" /> Psychosis is known to arises only very rarely from therapeutic use.<ref>Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf</ref><ref>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf</ref>
Abuse of compounds within the amphetamine chemical class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[paranoia]], [[External hallucinations|hallucinations]], or [[delusions]]).<ref name="amptreat">{{cite journal | vauthors=((Shoptaw, S. J.)), ((Kao, U.)), ((Ling, W.)) | veditors=((Cochrane Drugs and Alcohol Group)) | journal=Cochrane Database of Systematic Reviews | title=Treatment for amphetamine psychosis | date=21 January 2009 | url=https://doi.wiley.com/10.1002/14651858.CD003026.pub3 | issn=14651858 | doi=10.1002/14651858.CD003026.pub3}}</ref> A review on treatment for [[amphetamine]] and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref name="amptreat" /><ref>{{cite book | vauthors=((Hofmann, F. G.)) | date= 1983 | title=A handbook on drug and alcohol abuse: the biomedical aspects | publisher=Oxford University Press | edition=2nd ed | isbn=9780195030563}}</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref name="amptreat" /> Psychosis is known to arises only very rarely from therapeutic use.<ref>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf</ref>


===Dangerous interactions===
===Dangerous interactions===
Line 105: Line 105:
*'''Denmark''': Ethcathinone, along with mephedrone and flephedrone, was banned in Denmark on December 18, 2008.<ref>Forbud mod tre nye stoffer | http://nyheder.tv2.dk/article.php/id-19197033.html?forside=</ref>
*'''Denmark''': Ethcathinone, along with mephedrone and flephedrone, was banned in Denmark on December 18, 2008.<ref>Forbud mod tre nye stoffer | http://nyheder.tv2.dk/article.php/id-19197033.html?forside=</ref>
*'''Germany''': Ethylcathinone is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref> as of July 26, 2012.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl112s1639.pdf%27%5D|title=Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 25, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref>
*'''Germany''': Ethylcathinone is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref> as of July 26, 2012.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl112s1639.pdf%27%5D|title=Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 25, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref>
*'''United Kingdom''': Ethylcathinone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.<ref>United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made</ref>
*'''Poland''': Ethylcathinone is a Group I-P controlled substance.<ref>{{Citation | title=Ustawa z dnia 24 kwietnia 2015 r. o zmianie ustawy o przeciwdziałaniu narkomanii oraz niektórych innych ustaw (Dz.U. z 2015 r. poz. 875).
*'''United States''': Ethylcathinone may be considered to be an analogue of amphetamine under the Federal Analogue Act.The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.{{citation needed}}
  | url=https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20150000875}}</ref>
*'''Sweden''': Ethylcathinone in list I.<ref>https://www.lakemedelsverket.se/sv/lagar-och-regler/foreskrifter/2011-10-konsoliderad</ref>
*'''Switzerland''': Ethylcathinone is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': Ethylcathinone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2010 | url=https://www.legislation.gov.uk/uksi/2010/1207/made}}</ref>
*'''United States''': Ethylcathinone may be considered to be an analogue of amphetamine under the Federal Analogue Act.The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.<ref>{{Citation | title=21 U.S. Code § 813 - Treatment of controlled substance analogues | url=https://www.law.cornell.edu/uscode/text/21/813}}</ref>


==See also==
==See also==
Line 113: Line 117:
*[[Stimulants]]
*[[Stimulants]]
*[[Substituted cathinone]]
*[[Substituted cathinone]]
*[[Methcathinone]]
*[[Amphetamine]]
*[[Amphetamine]]